Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group

scientific article published on 01 July 1998

Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199807303390503
P698PubMed publication ID9696640

P433issue5
P407language of work or nameEnglishQ1860
P921main subjectaciclovirQ147101
preventionQ1717246
eye diseaseQ3041498
P304page(s)300-306
P577publication date1998-07-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleAcyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group
P478volume339

Reverse relations

cites work (P2860)
Q24202587Q24202587
Q35769258A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model
Q39638812A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells
Q35220431A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation
Q40867805A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo
Q30777273Accounting for misclassified outcomes in binary regression models using multiple imputation with internal validation data
Q34034789An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread
Q73904737Anterior uveitis with sectoral iris atrophy in the absence of keratitis: a distinct clinical entity among herpetic eye diseases
Q43775824Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model
Q37414696Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus
Q30847945Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B
Q40216595CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8+ TEM and CD8+ TRM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease
Q57488314Clinical Features of Herpes Simplex Keratitis in a Korean Tertiary Referral Center: Efficacy of Oral Antiviral and Ascorbic Acid on Recurrence
Q36816198Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis
Q34623643Clinical features and prognosis of herpetic anterior uveitis: a retrospective study of 111 cases
Q37443032Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient
Q89866345Concomitant herpetic keratitis and acute retinal necrosis: clinical features and outcomes
Q36359783Confocal Microscopic Analysis of a Rabbit Eye Model of High-Incidence Recurrent Herpes Stromal Keratitis.
Q44165410Corneal herpes: what's new?
Q37857665Corneal latency and transmission of herpes simplex virus-1.
Q80883371Current clinical practice of consultant ophthalmologists in treating herpetic eye disease in the United Kingdom
Q36555158Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.
Q42199077Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients.
Q47115686Decision-making and management of uveitic cataract
Q36199997Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation
Q36460600Diversity of microbial species implicated in keratitis: a review
Q33982508Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits
Q44605033Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial
Q41468795Effects of antiviral medications on herpetic epithelial keratitis in mice
Q46138251Efficacy and safety of latanoprost in eyes with uveitic glaucoma.
Q36626903Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection
Q36895307Evidence-based treatment of herpes simplex virus keratitis: a systematic review.
Q36025675Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine
Q27026675Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications
Q33654708Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures
Q34366070HSV-1 infection of human corneal epithelial cells: receptor-mediated entry and trends of re-infection.
Q95840901Herpes Simplex Virus: The Hostile Guest That Takes Over Your Home
Q44165415Herpes and retinal lesions: what's new?
Q34297293Herpes keratitis
Q26853504Herpes simplex epithelial and stromal keratitis: an epidemiologic update
Q37603658Herpes simplex keratitis: challenges in diagnosis and clinical management.
Q37949631Herpes simplex virus infects most cell types in vitro: clues to its success
Q37160338High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection
Q57753552Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107 CD8 T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect ag
Q35868029Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals
Q35012576Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis
Q36366295Increased neurovirulence and reactivation of the herpes simplex virus type 1 latency-associated transcript (LAT)-negative mutant dLAT2903 with a disrupted LAT miR-H2
Q44435875Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability
Q31983928LASIK complications: etiology, management, and prevention
Q37699098Large Amounts of Reactivated Virus in Tears Precedes Recurrent Herpes Stromal Keratitis in Stressed Rabbits Latently Infected with Herpes Simplex Virus
Q43187227Medical management approach to infectious keratitis
Q34757252Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells
Q90163562MicroRNAs in Ocular Infection
Q36520832Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections
Q44922924Necrotic herpetic retinitis
Q83839404Ocular herpes simplex
Q39024630Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts.
Q94569106Overview of antiviral medications used in ophthalmology
Q35590400Pathogenesis and management of herpes simplex virus keratitis
Q57476625Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation
Q37058919Practice patterns and opinions in the management of recurrent or chronic herpes zoster ophthalmicus
Q41882382Practice patterns for herpes simplex keratitis: A survey of ophthalmologists in Gulf Coast countries
Q34717035Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients
Q47547941Reactivation of herpes simplex viral keratitis following the botulinum toxin injection
Q52019903Recall bias in a prospective cohort study of acute time-varying exposures: example from the herpetic eye disease study.
Q43881072Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors
Q37767618Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate
Q33826410Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.
Q44922927The latest in herpes simplex keratitis therapy
Q35589785The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin
Q33722270The placebo effect
Q35113991The red eye in childhood
Q35745358Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of l
Q39840108Topical ganciclovir in the treatment of acute herpetic keratitis
Q80265715Topical treatment with nerve growth factor in an animal model of herpetic keratitis
Q21296712Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown
Q33805830Treatment of viral diseases of the cornea and external eye.
Q98726066Update on Herpes simplex keratitis management
Q41931288Update on the Management of Infectious Keratitis
Q41140880Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections.
Q30979930Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy
Q83745516["Herpetic keratitis". Various expressions require different therapeutic approaches]
Q54400543[Secondary glaucoma in uveitis].
Q80163758[Viral uveitis]

Search more.